Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened
Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Current Report on Form 8-K on January 12, 2026 to disclose an updated investor presentation used by management. The presentation was furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) and the report was signed by CEO Yuval Cohen.

Key Details

• Filing date: January 12, 2026; signed by Yuval Cohen, Chief Executive Officer.
• Item reported: 7.01 (Regulation FD Disclosure) — updated management presentation furnished as Exhibit 99.1.
• Additional exhibit: 104 (Cover Page Interactive Data File embedded in Inline XBRL).
• The 8-K does not report earnings, financial results, executive changes, or other material items beyond the furnished presentation.

Why It Matters
An updated investor presentation can provide refreshed detail on Corbus’s business strategy, pipeline, or milestones and is intended for broad investor communication under Regulation FD. Retail investors should review Exhibit 99.1 for any new disclosures or slide updates that could affect their view of the company; however, this 8-K itself does not contain financial results or management changes.